Results 71 to 80 of about 19,249 (228)

Antithrombin: Deficiency, Diversity, and the Future of Diagnostics

Mass Spectrometry Reviews, EarlyView.
ABSTRACT Our healthcare system provides reactive sick‐care, treating patients after symptoms have appeared by prescription of generic and often suboptimal therapy. This strategy brings along high costs and high pressure which is not sustainable.
Mirjam Kruijt, Christa M. Cobbaert, L. Renee Ruhaak   +2 more
wiley   +1 more source

Diagnosis and Treatment of Acquired Hemophilia A (AHA) with Bullous Pemphigoid

Jurnal Penyakit Dalam Indonesia, 2016
Acquired hemophilia A is a condition in which coagulation factor VIII become inactive due to autoantibody formation. This condition is related to pregnancy, malignancy, and autoimmune disease with skin disorder. In this case report, a 66 years woman with
Rasco Sandy Sihombing, Henry Ratno Diono Silalahi, Hamzah Shatri, Lugyanti Sukrisman, Ikhwan Rinaldi, Findy Prasetyawati, Endy Novianto, Em Yunir   +7 more
doaj   +1 more source

Consensus recommendations for the diagnosis and treatment of acquired hemophilia A [PDF]

, 2010
Background Acquired hemophilia A (AHA) is a rare bleeding disorder caused by an autoantibody to coagulation factor (F) VIII. It is characterized by soft tissue bleeding in patients without a personal or family history of bleeding.
Angela Huth-Kühne, Craig M Kessler, Francesco Baudo, Hervé Lévesque, Jean St-Louis, Jørgen Ingerslev, Maria Castellano, Midori Shima, Peter Collins   +8 more
core   +2 more sources

Sperm Sexing in Selected Animals and Humans: Methods, Applications, and Future Prospects

Andrology, EarlyView.
ABSTRACT Background Sperm sexing is a technique that enables the selection of offspring sex by sorting spermatozoa based on their sex chromosomes. This technology has gained increasing attention due to its potential applications in both animal breeding and human‐assisted reproduction.
Domrazek Kinga, Jurka Piotr
wiley   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Safety and Efficacy of Damoctocog Alfa Pegol Prophylaxis in Patients With Severe Haemophilia A: Results of an Interventional, Post‐Marketing Study

Haemophilia, EarlyView.
ABSTRACT This is a plain language summary of the results of a trial of damoctocog alfa pegol (BAY 94–9027, Jivi).
Pål André Holme, Lone Hvitfeldt Poulsen, Claudia Tueckmantel, Monika Maas Enriquez, María Teresa Alvarez Román, Raimondo De Cristofaro   +5 more
wiley   +1 more source

ORAL TREATMENT OF HEMOPHILIA [PDF]

, 2007
Disclosed herein is a simple method for the treatment of antigen-deficiency diseases, by orally administering to a subject a therapeutically effective amount of the deficient antigen, wherein the antigen is not present in a liposome.
Alpan, Oral, Kamala, Tirumalai, Matzinger, Polly, Velander, William Hugold   +3 more
core   +1 more source

Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions [PDF]

, 2014
International audienceAdeno-associated virus (AAV) vectors are one of the most efficient in vivo gene delivery platforms. Over the past decade, clinical trials of AAV vector-mediated gene transfer led to some of the most exciting results in the field of ...
Etiena Basner-Tschakarjan, Federico Mingozzi   +1 more
core   +3 more sources

Hemophilia Severity and Its Association With Mental Health and Health‐Related Quality of Life—Results From a Cross‐Sectional Multicenter Study

Haemophilia, EarlyView.
ABSTRACT Background Limited existing research on mental health and health‐related quality of life (HRQoL) in people with hemophilia (PwH) suggests these patients still may have poor mental health despite treatment advances significantly improving somatic outcomes.
Francesca Schmitt, Laura Maier, Stefan Lerch, Manuela Albisetti, Alice Trinchero, Lukas Graf, Heinz Hengartner, Pierre Fontana, Nicolas von der Weid, Katrin Scheinemann, Sylvia von Mackensen, Corinna Reichl, Marialuisa Cavelti, Ines Mürner‐Lavanchy, Johanna A. Kremer Hovinga, Michael Kaess, Mutlu Kartal‐Kaess   +16 more
wiley   +1 more source

Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention

Research and Practice in Thrombosis and Haemostasis, 2019
Essentials Acquired hemophilia A is a rare bleeding disorder often accompanied by other comorbidities. We describe emicizumab use in acquired hemophilia A complicated by acute coronary syndrome.
Kathryn E. Dane, John P. Lindsley, Michael B. Streiff, Alison R. Moliterno, Mian K. Khalid, Satish Shanbhag   +5 more
doaj   +1 more source